Avantor, Moderna, and Bristol-Myers Squibb are companies operating in the healthcare industry, with Avantor supplying materials to biopharma.
3 reports, 2 independent
Updated Sep 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Avantor, Moderna, and Bristol-Myers Squibb are companies operating in the healthcare industry, with Avantor supplying materials to biopharma.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Avantor
U.S. chemical company
-
Moderna
American biotechnology company
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Both Avantor and Azenta are healthcare companies in life sciences, with Azenta operating in North America and global markets.
- Bristol-Myers Squibb has taken ownership of Celgene's drug.
- Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.
Coverage
Newest first; wire copies grouped- StockStory3 Healthcare Stocks with Warning Signs From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged re
- StockStoryAvantor (NYSE:AVTR) Exceeds Q2 Expectations But Stock Drops Life sciences company Avantor (NYSE:AVTR) announced better-than-expected revenue in Q2 CY2025, but sales fell by 1.1% year on year to $1.68
- PR NewswireAvantor® Reports Second Quarter 2025 Results Net sales of $1.68 billion, decrease of 1%; organic revenue was flat Net income of $65 million; Adjusted EBITDA of $280 million Diluted GAAP EPS of $0.09;